US EditionWuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity
- WuXi XDC announced the GMP release of its new Drug Product 3 facility at its Wuxi site, marking a significant step in expanding drug product manufacturing capacity.
- The DP3 facility has an expected annual capacity of 7 million vials, contributing to a total capacity of approximately 15 million vials across three facilities.
- The facility was completed in 18 months, showcasing WuXi XDC's efficiency in design, construction, and qualification processes.
- The DP3 facility complies with GMP regulations from the FDA, EMA, and NMPA, ensuring high international quality standards.
Insights by Ground AI
Does this summary seem wrong?
68 Articles
68 Articles
LoudounTimes.com+67 Reposted by 67 other sources
WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity
WUXI, China, Aug. 4, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the Drug Product 3 ("DP3") facility at…
Coverage Details
Total News Sources68
Leaning Left6Leaning Right8Center26Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
15%
C 65%
R 20%
Factuality
To view factuality data please Upgrade to Premium
